Regional neuropathology in schizophrenia: Where are we? Where are we going?

Schizophrenia Research

Volumn 10, Issue 3, 1993, Pages 187-239

  Shapiro, Raymond M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

(Schizophrenia); Clinicopathologic correlation; Neuropathology; Neuropharmacology; Neurotransmitter uptake site; Postmortem; Receptor

Indexed keywords

BRAIN DEVELOPMENT; BRAIN INJURY; HUMAN; HUMAN TISSUE; NEUROPATHOLOGY; NEUROTRANSMISSION; PRIORITY JOURNAL; REGIONALIZATION; REVIEW; SCHIZOPHRENIA;

BRAIN; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; HUMAN; NEURAL PATHWAYS; NEUROTRANSMITTERS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUPPORT, NON-U.S. GOV'T;

EID: 0027362439     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/0920-9964(93)90057-P     Document Type: Review

References (195)

1. Morphometric analysis of synaptic contacts in the anterior limbic cortex in the endogenous psychoses
2. The hippocampus and parahippocampus in schizophrenic, suicide and control brains
3. Hippocampal pyramidal cell orientation in schizophrenia
4. The relationship between schizophrenic language and the aphasias
5. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease
6. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia
7. Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia
8. Lesions of the nucleus ansae peduncularis in neuropsychiatric disease
9. Structural lesions of the brain in young schizophrenics
10. Neurological consequences of industrial exposure to MPTP
11. Exposure to influenza epidemics during gestation and adult schizophrenia
12. Effects of age and diagnosis on thyrotropin response to thyrotropin-releasing hormone in psychiatric patients
13. Morphometry of the entorhinal cortex
14. An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients
15. Quantitative cytoarchtectual studies of the cerebral cortex of schizophrenics
16. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients
17. Increased vertical axon numbers in cingulate cortex of schizophrenics
18. Reduced neuronal size in posterior hippocampus of schizophrenic patients
19. Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain
20. Increased GABAa receptor binding in superficial layers of cingulate cortex in schizophrenics
21. Neurotransmitter receptors in frontal cortex of schizophrenics
22. Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates
23. Corpus callosum thickness in chronic schizophrenia
24. Response to Beckmann and Heinsen
25. A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients and schizophrenics
26. Basal ganglia and limbic system pathology in schizophrenia
27. Post-mortem volume measurements of limbic system and basal ganglia structures in chronic schizophrenics. Initial results from a new brain collection
28. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results
29. Postmortem evidence of structural brain changes in schizophrenia
30. Schizophrenia and the brain: a prospective clinico-neuropathological study
31. The frontal lobes, basal ganglia and temporal lobes as sites for schizophrenia
32. A unifying theory of movement and madness: involvement of free radicals in disorders of the isodendritic core of the brainstem
33. Gliosis in schizophrenia (letter)
34. Astrocytosis in the molecular layer of the dentate gyrus: a study in Alzheimer's disease and schizophrenia
35. Neuropathological findings in a suspected case of childhood schizophrenia
36. Normal nucleolar size of entorhinal cortex cells in schizophrenia (letter)
37. Twin birth and adult psychiatric disorder. An examination of the case records of the Maudsley Hospital
38. A quantitative investigation of hippocampal pyramidal cell size, shape and variability of orientation in schizophrenia
39. The effects of serotonin on the morpho-functional development of rat cerebral neocortex in tissue culture
40. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia
41. White matter reduction in the parahippocampal gyrus of patients with schizophrenia
42. Hippocampal pyramidal cell disarray in schizophrenia as a bilateral phenomenon
43. Global attentional deviance in children at risk for schizophrenia: specificity and predictive validity
44. Social competence and positive and negative symptoms: a longitudinal study of children and adolescents at risk for schizophrenia and affective disorder
45. Psychoses of obscure pathology
46. A clinical and pathological study of akinetic mutism
47. Chemical and structural changes in the brain in patients with movement disorder
48. The biology of schizophrenia
49. Limbic/mesolimbic connections and the pathogenesis of schizophrenia
50. Disorders of verbal output: mutism, aphasia and psychotic speech
51. The pathological anatomy of the schizophrenias
52. Schizophrenia-like psychoses associated with organic cerebral disorder: a review
53. Schizophrenia-like psychoses associated with organic disorders of the CNS: a review of the literature
54. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia
55. Prediction of adult-onset schizophrenia from childhood home movies of the patients
56. The nucleus basalis of Meynert, senile plaques and intellectual impairment in schizophrenia
57. High-risk research in schizophrenia: a summary of what has been learned
58. Cell loss in the hippocampus of schizophrenics
59. Loss of sylvian fissure asymmetry in schizophrenia: A quantitative post mortem study
60. Limbic pathology in schizophrenia: the entorhinal region - a morphometric study
61. Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients
62. Misidentification-Reduplication and the Right Hemisphere
63. The brain stem in psychosis
64. Towards a neuropsychology of schizophrenia
65. The role of the limbic system in experiential phenomena of temporal lobe epilepsy
66. The neuropsychology of schizophrenia
67. Sodium-dependent D-aspartate ‘binding’ is not a measure of presynaptic neuronal uptake sites in an autoradiographic assay
68. Studies in postmortem dopamine uptake II. Alterations of the synaptosomal catecholamine uptake in postmortem brain regions in schizophrenia
69. Mental phenomena evoked by electrical stimulation of the human hippocampal formation and amygdala
70. 3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics
71. Neuropathology of the brain stem in psychiatric disorders
72. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia
73. Limbic structures and lateral ventricle in schizophrenia: a quantitative postmortem study
74. Cortex, white matter and basal ganglia in schizophrenia: a volumetric postmortem study
75. Significance and meaning of neurological signs in schizophrenia
76. Neonatal lesions of the basal forebrain cholinergic neurons results in abnormal cortical development
77. An integrated neuropathophysiological model of schizophrenia
78. Recent studies of psychophysiology in schizophrenia
79. Neuroanatomical and neurochemical pathology in schizophrenia
80. The brain in schizophrenia
81. NMDA-associated glycine binding site increases in schizophrenic brains (letter)
82. Prenatal developmental disturbances in the limbic allocortex in schizophrenics
83. Gross and histological criteria for developmental disorders in brains of schizophrenics
84. Neuromorphological background of pathochemical studies in major psychoses
85. Hippocampal pathologic findings in schizophrenia: a morphometric study
86. Distribution of beta-adrenergic receptor subtypes in human post-mortem brain: alterations in limbic regions of schizophrenics
87. Effects of neonatal thermal lesioning of the mesocortical dopaminergic projection on the development of the rat prefrontal cortex
88. Effect of famotidine on deficit symptoms of schizophrenia
89. The brain stem reticular formation in schizophrenia
90. Increased forskolin binding in the left parahippocampal gyrus and CA1 region in post mortem schizophrenic brain determined by quantitative autoradiogra
91. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem
92. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia
93. Distribution of CCK binding sites in the human hippocampal formation and their alteration in schizophrenia: a post-mortem autoradiographic study
94. Serotonin uptake into astrocytes and its implications
95. Identification of high affinity serotonin uptake into immunocytochemically identified astrocytes
96. Commentary: The acquisition and use of human brain tissue in neuropsychiatric research
97. Anatomical neuropathology in schizophrenia: post-mortem findings
98. The neuropathology of schizophrenia
99. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
100. Case records of the Massachusetts General Hospital Weekly clinicopathological exercises Case 39-1988 A 76-year-old man with confusion agitation and gait disorder
101. A neurohistological correlate of schizophrenia
102. a-[3H]Amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to human cerebral cortical membranes: minimal changes in postmortem brains of chronic schizophrenics
103. Chronic parkinsonism in humans due to a product of meperidine analog synthesis
104. Ontogeny of the serotonergic system in the rat: serotonin as a developmental signal
105. Ontogeny of monoamine neurons in the locus coeruleus, raphe nuclei and substantia nigra of the rat. I. Cell differentiation
106. The diencephalon in schizophrenia: evidence for reduced thickness of the periventricular grey matter
107. Obstetric complications, neurodevelopmental deviance and risk of schizophrenics
108. Cerebral serotonin in viral encephalitis
109. Cerebellar pathology in schizophrenia? A neuronometric study
110. Locus ceruleus morphometry in aging and schizophrenia
111. Basal ganglia glucose metabolism asymmetry during a catatonic episode
112. Pathology, phenomenology and the dopamine hypothesis of schizophrenia
113. Evidence for the 5-HT hypothesis of suicide: a review of post-mortem studies
114. Pathogenesis of neuroleptic malignant syndrome
115. Motor abnormalities in schizophrenia
116. 2-Adrenoceptors in the brain of suicide victims: Increased receptor density associated with major depression
117. Neurological signs and the positive-negative dimension in schizophrenia
118. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics
119. Serotonergic neuronal systems: what their anatomic organization tells us about function
120. Stimulation of ornithine decarboxylase by histamine or norepinephrine in brain regions of the developing rat: evidence for biogenic amines as trophic agents in neonatal brain development
121. Is schizophrenia a neurodevelopmental disorder?
122. The neurodevelopmental origins of dementia praecox
123. Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia
124. A histological study of the corpus callosum in chronic schizophrenia
125. Neurpathology of the corpus callosum in schizophrenia (letter)
126. 3H]kainic acid binding in the prefrontal cortex in schizophrenia
127. G-proteins (Gi, Go) in the basal ganglia of control and schizophrenic brain
128. G proteins (Gi, Go) in the medial temporal lobe in schizophrenia: preliminary report of a neurochemical correlate of structural change
129. Neurotransmitter receptors in brain in schizophrenia
130. Post-mortem study of chronic schizophrenic brains
131. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenic
132. The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics
133. The brain's record of auditory and visual experience
134. The pathological physiology of signs and symptoms of coma
135. Analysis of [3H]neurotensin receptors by computerized densitometry visualization of central and peripheral neurotensin receptors
136. Herpes encephalitis with catatonic stupor
137. Structural brain abnormalities in the major psychoses: a quantitative review of the evidence from computerized imaging
138. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-1991
139. Cerebellar vermis in schizophrenia
140. Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia
141. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia
142. The case for frontostriatal dysfunction in schizophrenia
143. Schizophrenia: the cellular biology of a functional psychosis
144. Notes from the graveyard: neuropathology and schizophrenia
145. Response to letter by Casanova et al. (1987)
146. Gliosis in schizophrenia: a survey
147. Is there gliosis in schizophrenia? Investigation of the temporal lobe
148. The neuropathology of schizophrenia - a progress report
149. Subcortical lesions and aphasia
150. Effect of histamine on the development of astroglial cells in culture
151. Neuropsychiatry of movement disorders
152. Quantitative brain measurements in chronic schizophrenia
153. Analysis of laminar distribution of kappa opiate receptor in human cortex: comparison between schizophrenia and normal
154. Catatonia with frontal lobe atrophy
155. Herpes encephalitis with catatonic stupor
156. Neuropsychological function in schizophrenia: selective impairment in memory and learning
157. Disorientation of the hippocampal pyramidal cell and its processes in the schizophrenic patient
158. Animal models of schizophrenia: the hippocampally lesioned animal
159. Dopamine receptors and transporters in Parkinson's disease and schizophrenia
160. Evidence of glutamatergic deficiency in schizophrenia
161. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics
162. Sigma receptors in schizophrenic cerebral cortices
163. Reduced GABA uptake sites in the temporal lobe in schizophrenia
164. Alterations in phencyclidine and sigma binding sites in schizophrenic brains: effects of disease process and neuroleptic medication
165. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia
166. Catatonia in the presence of midbrain and brainstem abnormalities
167. Quantitative study of gliosis in schizophrenia and Huntington's chorea
168. Neuropathology of schizophrenia
169. Clinicopathological correlations in schizophrenia (letter)
170. Higher cognitive functions
171. Cerebral lesions simulating schizophrenia: three case reports
172. Raphe nuclei and serotonin containing systems
173. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients
174. The psychoses of epilepsy and the functional psychoses: A clinical and phenomenological comparison
175. Serotonergic innervation of the rat caudate following a neonatal 6-hydroxydopamine lesion: an anatomical, biochemical and pharmacological study
176. Psychopathology of frontal lobe syndromes
177. First-rank symptoms of Schneider: a new perspective?
178. Neuropsychiatric disturbances following brainstem lesions
179. The major hallucinogens and the central cytoskeleton: an association beyond coincidence? Towards sub-cellular mechanisms in schizophrenia
180. Effect of cocaine use on the fetus
181. Schizophrenia, neurodevelopment and disease
182. A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia and L-dopa-induced chorea
183. Implications of normal brain development for the pathogenesis of schizophrenia
184. Cerebellar pathology in schizophrenia: a controlled postmortem study
185. Neuropathological studies of schizophrenia: A selective review
186. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia
187. Limited supplies of brain tissue hamper research: shortages a problem for those studying psychiatric disorders
188. Tritiated LSD binding in frontal cortex in schizophrenia
189. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxy- methamphetamine
190. Neurologic abnormalities in schizophrenic patients and their families: I. Comparison of schizophrenic, bipolar and substance abuse patients and normal controls
191. Schizophrenia, just the facts: What do we know, how well do we know it?
192. The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls